Ozempic to Send Foodmakers Looking for Healthier Offerings
Companies should consider smaller portions, fresh ingredients or offloading unhealthy brands as weight-loss drugs take off, respondents say.
Photographer: Peter Dazeley/The Image Bank RF/Getty Images
This article is for subscribers only.
Companies selling unhealthy foods need to tweak their business models to counter the growing popularity of weight-loss drugs — or risk alienating investors, according to the latest Bloomberg Markets Live Pulse survey.
Nearly three out of four respondents said companies making or marketing sugary, fatty or ultra-processed foods should revise their game plans, either by shrinking portions, adjusting recipes or offloading assets altogether. Just over a quarter of the 303 respondents think Big Food can wait out the emerging threat from appetite-suppressing drugs like Zepbound, Ozempic and Wegovy.